S.Korea's Celltrion to merge with affiliates to set up holding company structure
SEOUL, Sept 25 (Reuters) - South Korean pharmaceutical
company Celltrion 068270.KS said in a regulatory filing on
Friday that it plans to merge with affiliates Celltrion
HealthCare 091990.KQ , Celltrion Pharm 068760.KQ to establish
a holding company structure by end-2021.
Celltrion, whose experimental COVID-19 treatment has been
approved by South Korea for Phase 2/3 clinical trials, said the
merger will take place when requirements for South Korean fair
trade rules are met. urn:newsml:reuters.com:*:nL4N2GE2SN
(Reporting by Joyce Lee. Editing by Jane Merriman)
((jungyoon.lee@tr.com; +82 2 6936 1467;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap